X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15235) 15235
Book Review (3395) 3395
Publication (1474) 1474
Book Chapter (153) 153
Book / eBook (147) 147
Newsletter (121) 121
Patent (99) 99
Newspaper Article (77) 77
Conference Proceeding (42) 42
Magazine Article (11) 11
Dissertation (8) 8
Transcript (4) 4
Reference (2) 2
Trade Publication Article (2) 2
Data Set (1) 1
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13486) 13486
humans (10177) 10177
animals (5832) 5832
male (5393) 5393
female (5008) 5008
peptides (4011) 4011
middle aged (3033) 3033
aged (2518) 2518
mice (2330) 2330
proteins (2049) 2049
adult (1979) 1979
peptide fragments - blood (1950) 1950
analysis (1778) 1778
pharmacology & pharmacy (1711) 1711
biochemistry & molecular biology (1562) 1562
cardiac & cardiovascular systems (1526) 1526
rats (1498) 1498
research (1408) 1408
biomarkers - blood (1354) 1354
abridged index medicus (1293) 1293
natriuretic peptide, brain - blood (1287) 1287
immunology (1271) 1271
treatment outcome (1223) 1223
health aspects (1215) 1215
peptide fragments - therapeutic use (1194) 1194
risk factors (1167) 1167
neurosciences (1115) 1115
article (1022) 1022
care and treatment (1012) 1012
physiological aspects (992) 992
expression (989) 989
mortality (986) 986
alzheimer's disease (969) 969
amino acid sequence (963) 963
peptide fragments - pharmacology (940) 940
time factors (939) 939
prognosis (923) 923
cancer (921) 921
peptide fragments - metabolism (917) 917
heart failure (910) 910
peptide fragments - adverse effects (897) 897
medicine (895) 895
cell biology (893) 893
disease models, animal (882) 882
endocrinology & metabolism (875) 875
research article (861) 861
natriuretic peptides (852) 852
molecular sequence data (813) 813
multidisciplinary sciences (779) 779
medicine, research & experimental (778) 778
aged, 80 and over (776) 776
gene expression (773) 773
inflammation (761) 761
peptide fragments - administration & dosage (745) 745
prospective studies (745) 745
rodents (743) 743
biomarkers (732) 732
in-vivo (729) 729
oncology (725) 725
peptide (713) 713
enzymes (710) 710
drug therapy (701) 701
dose-response relationship, drug (692) 692
medicine & public health (684) 684
disease (681) 681
immunotherapy (667) 667
apoptosis (661) 661
studies (631) 631
mice, inbred c57bl (618) 618
science (618) 618
biotechnology & applied microbiology (616) 616
in-vitro (614) 614
medical research (601) 601
diagnosis (597) 597
recombinant proteins - therapeutic use (596) 596
peptide fragments - immunology (594) 594
brain natriuretic peptide (590) 590
protein (581) 581
therapy (581) 581
cells (564) 564
cardiology (562) 562
diabetes (557) 557
cells, cultured (555) 555
rats, sprague-dawley (552) 552
biochemistry (547) 547
antibodies (546) 546
clinical trials (544) 544
brain (543) 543
surgery (536) 536
alzheimers-disease (532) 532
oxidative stress (531) 531
genetic aspects (528) 528
biology (524) 524
amino acids (517) 517
follow-up studies (513) 513
activation (510) 510
physiology (510) 510
hematology (504) 504
lipids (501) 501
risk (498) 498
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (105) 105
UofT at Mississauga - Stacks (12) 12
Collection Dvlpm't (Acquisitions) - Vendor file (8) 8
Chemistry (A D Allen) - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
UTL at Downsview - May be requested (4) 4
Engineering & Comp. Sci. - Stacks (3) 3
Robarts - Stacks (3) 3
Gerstein Science - Periodical Stacks (2) 2
UofT at Scarborough - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Reference (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Mississauga - Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15583) 15583
French (53) 53
German (48) 48
Chinese (44) 44
Japanese (29) 29
Spanish (28) 28
Russian (20) 20
Italian (9) 9
Czech (8) 8
Polish (4) 4
Portuguese (4) 4
Danish (3) 3
Dutch (2) 2
Hungarian (2) 2
Turkish (2) 2
Bosnian (1) 1
Croatian (1) 1
Finnish (1) 1
Korean (1) 1
Norwegian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 04/2015, Volume 313, Issue 13, pp. 1336 - 1346
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2011, Volume 365, Issue 21, pp. 1980 - 1989
This trial compared the combination of abciximab and unfractionated heparin with bivalirudin in patients with non–ST-segment elevation MI who were undergoing... 
ELUTING STENTS | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | CLOPIDOGREL | PRETREATMENT | CLINICAL-TRIALS | PLATELET | PCI | RANDOMIZED-TRIAL | BLOCKADE | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Recurrence | Myocardial Infarction - mortality | Humans | Immunoglobulin Fab Fragments - adverse effects | Middle Aged | Thrombin - antagonists & inhibitors | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Recombinant Proteins - adverse effects | Heparin - adverse effects | Angioplasty, Balloon, Coronary | Myocardial Infarction - therapy | Adult | Female | Drug Therapy, Combination | Double-Blind Method | Angina Pectoris - drug therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Myocardial Infarction - drug therapy | Hirudins - adverse effects | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Abciximab | Drug utilization | Bivalirudin | Heparin | Comparative analysis | Drug therapy | Heart attack | Myocardial infarction | Heart attacks | Monoclonal antibodies | Biomarkers | Death | Acute coronary syndromes | Bleeding | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 20, pp. 1956 - 1964
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2013, Volume 369, Issue 23, pp. 2207 - 2217
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2008, Volume 358, Issue 21, pp. 2218 - 2230
Bivalirudin is a direct thrombin inhibitor. As compared with a combination of heparin and a glycoprotein IIb/IIIa inhibitor, bivalirudin use resulted in less... 
MEDICINE, GENERAL & INTERNAL | IMPACT | THERAPY | GLYCOPROTEIN IIB/IIIA BLOCKADE | BLOOD-TRANSFUSION | ACUTE CORONARY SYNDROMES | RANDOMIZED CONTROLLED-TRIAL | ACUITY TRIAL | INTERVENTION | ABCIXIMAB | CLINICAL-OUTCOMES | Recombinant Proteins - therapeutic use | Recurrence | Myocardial Infarction - mortality | Humans | Middle Aged | Heparin - therapeutic use | Male | Recombinant Proteins - adverse effects | Heparin - adverse effects | Angioplasty, Balloon, Coronary | Myocardial Infarction - therapy | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Antithrombins - therapeutic use | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Thrombosis - epidemiology | Combined Modality Therapy | Anticoagulants - adverse effects | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Myocardial Infarction - complications | Stroke - etiology | Thrombosis - etiology | Antithrombins - adverse effects | Hirudins - adverse effects | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Stents - adverse effects | Care and treatment | Coronary artery bypass | Bivalirudin | Drug therapy, Combination | Heparin | Comparative analysis | Health aspects | Heart attack | Stroke | Heart attacks | Ischemia | Cardiology | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2015, Volume 373, Issue 11, pp. 997 - 1009
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9951, pp. 1349 - 1357
Summary Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | EFFICACY | PHYSICAL-ACTIVITIES | SAFETY | PARALLEL-GROUP | EXENATIDE | ANALOG LIRAGLUTIDE | GATEKEEPING PROCEDURES | DAILY LIVING QUESTIONNAIRE | PEPTIDE-1 RECEPTOR AGONISTS | Metformin - therapeutic use | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Hypoglycemic Agents - administration & dosage | Fasting - blood | Female | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Treatment Outcome | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Type 2 diabetes | Usage | Research | Comparative analysis | Drug therapy | Clinical trials | Enzymes | Blood pressure | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9696, pp. 1149 - 1159
Summary Background In the HORIZONS-AMI trial, patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | IMPACT | GLYCOPROTEIN IIB/IIIA BLOCKADE | BLOOD-TRANSFUSION | RISK | ACUTE CORONARY SYNDROMES | ACUITY TRIAL | ABCIXIMAB | INTERVENTION | ANTIPLATELET THERAPY | CLINICAL-OUTCOMES | Recombinant Proteins - therapeutic use | Myocardial Infarction - mortality | Follow-Up Studies | Humans | Middle Aged | Heparin - therapeutic use | Male | Recombinant Proteins - adverse effects | Heparin - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Aged, 80 and over | Adult | Female | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Hemorrhage - epidemiology | Kaplan-Meier Estimate | Proportional Hazards Models | Anticoagulants - therapeutic use | Survival Rate | Treatment Outcome | Anticoagulants - adverse effects | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Myocardial Infarction - drug therapy | Thrombosis - etiology | Hirudins - adverse effects | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Stents - adverse effects | Care and treatment | Angioplasty | Patient outcomes | Bivalirudin | Dosage and administration | Health aspects | Heart attack | Clinical trials | Cardiovascular disease | Heart attacks | Drug therapy | Mortality | Index Medicus | Abridged Index Medicus
Journal Article